Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.45 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.36 |
| ▸ | ITGAL | P20701 | 2/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14188457 | 0.89 | CDC7 (0.50) | LRRK2CDC7PIM1PIM2 | |
| SCHEMBL14188515 | 0.87 | CDC7 (0.46) | LRRK2CDC7PIM1PIM2 | |
| SCHEMBL4994390 | 0.87 | CDC7 (0.46) | LRRK2CDC7KCNH2CTSSCTSK | |
| SCHEMBL5002366 | 0.86 | CDC7 (0.47) | LRRK2CDC7KCNH2PIM1PIM2 | |
| SCHEMBL4994946 | 0.86 | CDC7 (0.47) | LRRK2CDC7KCNH2PIM1PIM2 | |
| SCHEMBL14188574 | 0.85 | CDC7 (0.46) | LRRK2CDC7SYKPIM1PIM2 | |
| SCHEMBL4997506 | 0.85 | CDC7 (0.46) | CDC7PIM1PIM2 | |
| SCHEMBL4997114 | 0.85 | CDC7 (0.46) | LRRK2CDC7PIM1PIM2 | |
| SCHEMBL4997421 | 0.85 | CDC7 (0.46) | LRRK2CDC7PIM1PIM2 | |
| SCHEMBL4997439 | 0.85 | CDC7 (0.46) | LRRK2CDC7KCNH2CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | HANAU CATHLEEN E | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113971-A1 | PYRAZOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS | MKNK2, MAPKAPK2, MAP3K2 | LRRK2 577/4885CDC7 487/4885KCNH2 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.